Dinutuximab beta in high-risk neuroblastoma: a profile of its use

Dinutuximab beta in high-risk neuroblastoma: a profile of its use Drugs Ther Perspect https://doi.org/10.1007/s40267-018-0522-2 ADIS DRUG Q&A Dinutuximab beta in high-risk neuroblastoma: a profile of its use 1 1 Kate McKeage Katherine A. Lyseng-Williamson Springer International Publishing AG, part of Springer Nature 2018, corrected publication June/2018 Abstract Dinutuximab beta (Qarziba ), a monoclonal antibody, is indicated to treat high-risk neuroblastoma in Adis evaluation of dinutuximab beta in the treatment of high-risk neuroblastoma patients aged C 12 months in the first-line setting subse- quent to front-line treatment with induction chemotherapy, Monoclonal antibody that targets disialoganglioside 2, which is highly expressed on neuroblastoma cells myeloablative therapy and stem cell transplantation (SCT), Achieves objective clinical responses in the first-line setting as well as in the relapsed/refractory setting. It targets subsequent to induction chemotherapy, myeloablative therapy and disialoganglioside 2, which is highly expressed on neu- SCT and in the relapsed/refractory setting roblastoma cells. Unlike dinutuximab, which is produced Improves survival rates relative to historical controls treated in the using mouse SP2/0 cells, dinutuximab beta is produced pre-immunotherapy era using the more widely used Chinese hamster ovary cells. In Common toxicities (neuropathic pain, pyrexia, hypersensitivity both the first-line and relapsed/refractory settings, treat- reactions) are generally manageable with appropriate precautions ment with dinutuximab beta achieves http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Drugs & Therapy Perspectives Springer Journals

Dinutuximab beta in high-risk neuroblastoma: a profile of its use

Loading next page...
 
/lp/springer_journal/dinutuximab-beta-in-high-risk-neuroblastoma-a-profile-of-its-use-9KrDe4kkzY
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Pharmacy; Pharmacy; Pharmacotherapy
ISSN
1172-0360
eISSN
1179-1977
D.O.I.
10.1007/s40267-018-0522-2
Publisher site
See Article on Publisher Site

Abstract

Drugs Ther Perspect https://doi.org/10.1007/s40267-018-0522-2 ADIS DRUG Q&A Dinutuximab beta in high-risk neuroblastoma: a profile of its use 1 1 Kate McKeage Katherine A. Lyseng-Williamson Springer International Publishing AG, part of Springer Nature 2018, corrected publication June/2018 Abstract Dinutuximab beta (Qarziba ), a monoclonal antibody, is indicated to treat high-risk neuroblastoma in Adis evaluation of dinutuximab beta in the treatment of high-risk neuroblastoma patients aged C 12 months in the first-line setting subse- quent to front-line treatment with induction chemotherapy, Monoclonal antibody that targets disialoganglioside 2, which is highly expressed on neuroblastoma cells myeloablative therapy and stem cell transplantation (SCT), Achieves objective clinical responses in the first-line setting as well as in the relapsed/refractory setting. It targets subsequent to induction chemotherapy, myeloablative therapy and disialoganglioside 2, which is highly expressed on neu- SCT and in the relapsed/refractory setting roblastoma cells. Unlike dinutuximab, which is produced Improves survival rates relative to historical controls treated in the using mouse SP2/0 cells, dinutuximab beta is produced pre-immunotherapy era using the more widely used Chinese hamster ovary cells. In Common toxicities (neuropathic pain, pyrexia, hypersensitivity both the first-line and relapsed/refractory settings, treat- reactions) are generally manageable with appropriate precautions ment with dinutuximab beta achieves

Journal

Drugs & Therapy PerspectivesSpringer Journals

Published: May 23, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off